In Vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5255-5260

  Gansukh, Tserenchunt ^a   Donizy, Piotr ^b   Halon, Agnieszka ^b   Lage, Hermann ^c   Surowiak, Pawel ^b  

^a MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cisplatin resistance 97 97; DV90 cells; Immunocytochemistry; Metallothionein; Non small cell lung cancer

Indexed keywords

CISPLATIN; METALLOTHIONEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84891472568     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Volm M, Koomagi R, Mattern J and Efferth T: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87: 251-257, 2002.
2. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E and ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v116-v119, 2010.
3. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71: 3-10, 2011.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J and the International Adjuvant Lung Cancer Trial Collaborative Group: The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Eng J Med 350: 351-360, 2004.
5. Krizkova S, Ryvolova M, Hrabeta J, Adam V, Stiborova M, Eckschlager T and Kizek R: Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev 44: 287-301, 2012.
6. Cherian MG, Jayasura A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutation Res 533: 201-209, 2003.
7. Surowiak P, Matkowski R, Materna V, Györffy B, Wojnar A, Pudelko M, Dziegiel P, Kornafel J and Zabel M: Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol Histopathol 20: 1037-1044, 2005.
8. Surowiak P, Materna V, Gyorffy B, Matkowski R, Wojnar A, Maciejczyk A, Paluchowski P, Dziegiel P, Pudełko M, Kornafel J, Dietel M, Kristiansen G, Zabel M and Lage H: Multivariate analysis of oestrogen receptor α, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 95: 339-346, 2006.
9. Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H and Zabel M: Augmented expression of metallothionein and glutathione S-transferase π as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv 447: 626-633, 2005.
10. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J and Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18: 401-407, 2003.
11. Ohshio G, Imamura T, Okada N, Wang ZH, Yamaki K, Kyogoku T, Suwa H, Yamabe H and Imamura M: Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 122: 351-355, 1996.
12. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005.
13. Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M, Jankowska R and Dziegiel P: Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol 94: 301-308, 2013.
14. Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P and Jankowska R: Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res 31: 2833-2839, 2011.
15. Surowiak P, Materna V, Maciejczyk A, Pudełko M, Markwitz E, Spaczyński M, Dietel M, Zabel M and Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007.
16. Kaina B, Lohrer H, Karin M and Herrlich P: Overexpressed human metallothionein IIA gene protects Chinese hamster ovary from killing by alkylating agents. Proc Natl Acad Sci USA 87: 2710-2714, 1997.
17. Rosell R and Felip E: Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 28: 37-44: 2001.
18. Volm M and Rittgen W: Cellular predictive factors for the drug response of lung cancer. Anticancer Res 20: 3449-3458, 2000.
19. Hagrman D, Goodisman J, Dabrowiak JC and Souid AK: Kinetic study on the relation of cisplatin with metallothionein. Drug Metab Dispos 31: 916-923, 2003.
20. Materna V, Liedert B, Thomale J and Lage H: Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115: 393-402, 2005.
21. Kowalski P, Surowiak P and Lage H: Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/PGP, MRP2, and BCRP. Mol Ther 11: 508-522, 2005.
22. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
23. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
24. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43, 2001.
25. Matsumoto Y, Oka M, Sakamoto A, Narasaki F, Fukuda M, Takatani H, Terashi K, Ikeda K, Tsurutani J, Nagashima S, Soda H and Kohno S: Enhanced expression of metallothionein in human non-small cell lung carcinomas following chemotherapy. Anticancer Res 17: 3777-3780, 1997.